Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers.
Matthew R AronsonErika S DahlJacob A HalleAndrew W SimonsonRose A GogalAdam B GlickKatherine M AirdScott H MedinaPublished in: Cellular and molecular bioengineering (2020)
We show that cancer-specific ACPs can be rationally engineered using nature's AMP toolbox as templates. Selecting the antimicrobial peptide MAD1, we demonstrate the potential of this strategy to open a wealth of synthetic biotherapies that offer new, combinatorial opportunities against drug resistant tumors.